Camille L. Bedrosian - 01 Mar 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP and Chief Medical Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
01 Mar 2023
Net transactions value
-$175,615
Form type
4
Filing time
03 Mar 2023, 19:00:36 UTC
Previous filing
21 Jun 2022
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +2,663 +5.6% $0.000000 50,601 01 Mar 2023 Direct F1
transaction RARE Common Stock Sale $175,615 -3,881 -7.7% $45.25 46,720 01 Mar 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock into which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric.
F2 Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.